Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced preliminary top line results from PROPEL, the Company's pivotal Phase 2 trial of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE